Wyeth Pharmaceuticals – the division of Wyeth Group owns several foremost formulated preparations for the women’s healthcare sector, treatment of infectious diseases, drugs for gastrointestinal disorders, medications for the central nervous system, inflammation, transplantations, hemophilia, oncology, vaccines as well as several nutritional products.   Pristiq – Desvenlafaxine Succinate is used for the vasomotor symptoms of menopause, major depressive disorder, and Fibromyalgia as well as Neuropathic pains. Pristiq is the serotonin norepinephrine reuptake inhibitor – SNRI which is being studied by Wyeth as the possible treatment for multiple indications that includes mild to serious post menopausal hot flashes and sweatiness during nights.

Pristiq is thought to be functioning by affecting the balance of serotonin and norepinephrine, which are the chemicals better known as neurotransmitters and believed playing the vital role in the brain for controlling the body temperature; while they may have got imbalanced during the menopausal phase and end up developing hot flashes and night sweats. If Pristiq gets formal recognition from the U.S. FDA against the submission of official application by Wyeth for granting the permission to use the drug for the treatment of moderate to sever vasomotor symptoms accompanied by the menopausal phase; it would be the very first and probably the only non-hormonal medication indicated for the said treatment.        

Pristiq will be the first ever non-hormonal therapy drug which would be studied in the extended time of six and twelve months placebo controlled trials according to the statements revealed publicly. Pristiq is also under active considerations for its usage in the treatment of major depression disorders for which Wyeth has already received the authentication from the U.S. FDA.